TY - JOUR
T1 - Cardiovascular disease and toxicities related to HIV infection and its therapies
AU - Zareba, Karolina M.
AU - Miller, Tracie L.
AU - Lipshultz, Steven E.
PY - 2005/11/1
Y1 - 2005/11/1
N2 - Cardiovascular manifestations of HIV vary according to disease stage, treatment regimen and geographical location. Common cardiac complications of HIV disease in patients off highly active antiretroviral therapy (HAART) include dilated cardiomyopathy, myocarditis, pericardial effusion, endocarditis, pulmonary hypertension and non-antiretroviral drug-related cardiotoxicity. However, with the introduction of HAART that has substantially modified the course of HIV disease by lengthening survival, additional cardiovascular consequences are a result of the metabolic syndrome with a propensity toward hyperlipidaemia and atherosclerotic heart disease. Because most of the world's HIV-infected patients have not been treated with HAART, the principal HIV-associated cardiovascular manifestations of patients off HAART are reviewed and new knowledge about the prevalence, pathogenesis and treatment in the HAART era are emphasised in this review. Exercise, a nonpharmacological approach to treating HAART-associated metabolic syndrome, is also discussed.
AB - Cardiovascular manifestations of HIV vary according to disease stage, treatment regimen and geographical location. Common cardiac complications of HIV disease in patients off highly active antiretroviral therapy (HAART) include dilated cardiomyopathy, myocarditis, pericardial effusion, endocarditis, pulmonary hypertension and non-antiretroviral drug-related cardiotoxicity. However, with the introduction of HAART that has substantially modified the course of HIV disease by lengthening survival, additional cardiovascular consequences are a result of the metabolic syndrome with a propensity toward hyperlipidaemia and atherosclerotic heart disease. Because most of the world's HIV-infected patients have not been treated with HAART, the principal HIV-associated cardiovascular manifestations of patients off HAART are reviewed and new knowledge about the prevalence, pathogenesis and treatment in the HAART era are emphasised in this review. Exercise, a nonpharmacological approach to treating HAART-associated metabolic syndrome, is also discussed.
KW - AIDS
KW - Cardiomyopathy
KW - Cardiotoxicity
KW - Dyslipidaemia
KW - Exercise
KW - Highly active antiretroviral theraphy (HAART)
KW - HIV
UR - http://www.scopus.com/inward/record.url?scp=27944441787&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27944441787&partnerID=8YFLogxK
U2 - 10.1517/14740338.4.6.1017
DO - 10.1517/14740338.4.6.1017
M3 - Review article
C2 - 16255661
AN - SCOPUS:27944441787
VL - 4
SP - 1017
EP - 1025
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 6
ER -